CEPI, the Coalition for Epidemic Preparedness Innovations, has expanded its partnership with Sichuan Clover Biopharmaceuticals to rapidly advance the development and manufacture of Clover’s protein-based COVID-19 S-Trimer vaccine candidate, which is based on Clover’s proprietary Trimer-Tag vaccine technology platform.   CEPI will make an additional investment of $66 million upfront in S-Trimer which will immediately fund preclinical studies, the execution of Phase 1 clinical trials, and preparat...